Novartis Accuses MSN of Violating Revived Entresto Patent

MSN Laboratories Pvt. Ltd. infringed a recently revived Novartis AG patent by importing and preparing to distribute large quantities of its copies of the blockbuster heart-failure drug Entresto before the patent expires, according to a federal lawsuit.

MSN engaged in direct, induced, and contributory infringement of US Patent No. 8,101,659 when it imported more than 300,000 bottles of its generic Entresto in August 2024 and 2,200 kilograms of the drug’s active ingredient in December, according to a complaint docketed Tuesday in the US District Court for the District of Delaware. Novartis cited the US Court of Appeals for the Federal ...